MIRA Pharmaceuticals reports preclinical MIRA-55 pain study results comparable to celecoxib
MIRA Pharmaceuticals reported positive results from a 21-day preclinical study of oral MIRA-55 in a chronic inflammatory pain model, with pain relief it describes as comparable to celecoxib (Celebrex). The study is early-stage animal work, and the company plans an IND submission in the first quarter of 2027. The filing contains no financial results, so it does not change reported revenue, profit or guidance.
Key points
- Study used 72 male and female rats over 21 days in the Complete Freund's Adjuvant model, run by an independent contract research organization.
- MIRA-55 significantly reduced mechanical and thermal pain hypersensitivity versus vehicle (p < 0.001); no statistically significant difference from celecoxib was observed.
- Company plans an IND submission for MIRA-55 in the first quarter of 2027, subject to remaining preclinical and regulatory work.
- The U.S. Drug Enforcement Administration has determined MIRA-55 is not a controlled substance; safety and efficacy in humans have not been established.
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 22, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.